Surgical Safety Technologies delivers data-driven AI technology to hospitals for safe surgeries. It empowers surgeons with an objective assessment of technical and non-technical proficiency using academically validated frameworks.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Access Optics is able to combine innovating manufacturing engineering, process development, and optical fabrication with advanced coating technology. The pioneering product development and advanced materials solutions have fostered breakthrough products for leading OEMs in endoscopy, dermatology, aerospace, and chromatography.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
KēlaHealth is a software platform that combines predictive algorithms with high-impact interventions to reduce surgical complications. They use millions of data points to inform each patient's comprehensive risk profile, then recommend the best interventions to mitigate those risks. By following every surgical journey end-to-end, from prediction and action to outcomes, they continuously improve and inform the surgical quality ecosystem.
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
Glyscend, Inc. is a company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes. Founded in 2014 and based in Baltimore, Maryland, Glyscend has created a non-invasive, orally ingestible intestinal coating designed to mimic the effects of bariatric surgery without the need for surgical intervention. This coating works by preventing the stimulation of the duodenal mucosa and inhibiting critical neurohormonal pathways in the proximal gut, thereby helping to regulate glucose levels effectively. The company's approach aims to offer patients a viable solution for managing their condition while minimizing side effects commonly associated with diabetes treatments, such as weight gain and hypoglycemia. Glyscend seeks to empower healthcare providers, including endocrinologists and primary care physicians, with effective tools to address type 2 diabetes more comprehensively rather than simply managing its symptoms.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Remedy provides an on-demand urgent and primary care service focusing on innovative delivery of care. Remedy delivers medical care in the form of 24/7 telemedicine and nurse access, lab visits, and house calls, for individual patients and large employer clients, enabling patients to get quality doorstep treatment at an affordable price.
Remedy was founded in 2015 and is based in Austin, Texas.
Geneos Therapeutics, Inc. specializes in the production and development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and based in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are specifically tailored to the unique tumor mutations of each patient. By identifying relevant neoantigen targets from individual tumors, Geneos aims to develop innovative treatments that provide targeted immunotherapies for cancer patients, enhancing the potential for effective disease management and cure.
Endogenex
Series A in 2018
DyaMX is developing therapies for GI and metabolic disease processes.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
CryOSA, Inc., a medical device company, develops novel treatments for patients with sleep disordered breathing. It offers therapies for obstructive sleep apnea. CryOSA, Inc. was incorporated in 2014 and is based in Roseville, Minnesota.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
Millipede Inc. develops percutaneous solutions for mitral valve repair. The company was incorporated in 2012 and is based in Santa Rosa, California. As of January 29, 2019, Millipede Inc. operates as a subsidiary of Boston Scientific Corporation.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Lyric Pharmaceuticals Inc., a clinical-stage pharmaceutical company, develops therapeutics to improve the care of critically ill and hospitalized patients. The company develops ulimorelin, a macrocyclic agonist of the hormone ghrelin, as LP101 for the treatment of enteral feeding intolerance and for other disorders affecting critically ill patients in the ICU. It develops therapeutics for gastrointestinal indications. The company was founded in 2013 and is headquartered in South San Francisco, California.
Laguna Pharmaceuticals Inc. develops and markets drugs and small molecule pharmaceuticals vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company was formerly known as ChanRx Corp. and changed its name to Laguna Pharmaceuticals Inc. in February, 2015. Laguna Pharmaceuticals Inc. was founded in 2006 and is based in La Jolla, California.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Guided Interventions is a Cleveland-based medical device startup Led by CEO Dr. Matthew Pollman, Guided Interventions develops a a fractional flow reserve (FFR) guidewire that is designed to provide an effective way to obtain FFR measurements during coronary catheterization procedures. It is optimized for improved maneuverability and handling.
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and manage their health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Healthcare Highways, Inc. operates as an accountable care organization and health plan that partners with hospitals, providers, employers, payers, and brokers/consultants to deliver customized healthcare plan solutions. Its customizable health plans cover TPA administration, stop-loss coverage, disease management, pharmacy benefit management services, and population health. The company was founded in 2012 and is based in Frisco, Texas.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
Rex Bionics Ltd. is a New Zealand-based company that specializes in the development and manufacturing of robotic medical equipment aimed at rehabilitation. Incorporated in 2007, the company produces the REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Rex Bionics focuses on improving the physical and psychological well-being of people affected by spinal cord injuries, strokes, traumatic brain injuries, and neurodegenerative diseases. The company's primary products include the REX and the REX P (Personal), which cater to both professional neuro-rehabilitation clinics and personal homecare markets. Through innovative technology, Rex Bionics aims to enhance the rehabilitation experience for individuals facing significant mobility challenges.
At AbVitro, they are committed to advancing the treatment of poorly understood human diseases with an underlying immune component. Their mission is to harness the power of the human immune system and its role in complex diseases to uncover new potential therapeutic targets or biomarkers, while simultaneously discovering and evaluating their respective fully human antibody binders for therapeutic potential. Simply put, They find new therapeutic targets with matching therapeutic antibodies and/or T cell receptors (TCRs) in diseases with unmet medical needs.
LumaTherm
Series A in 2012
LumaTherm, Inc.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Laguna Pharmaceuticals Inc. develops and markets drugs and small molecule pharmaceuticals vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company was formerly known as ChanRx Corp. and changed its name to Laguna Pharmaceuticals Inc. in February, 2015. Laguna Pharmaceuticals Inc. was founded in 2006 and is based in La Jolla, California.
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Millipede Inc. develops percutaneous solutions for mitral valve repair. The company was incorporated in 2012 and is based in Santa Rosa, California. As of January 29, 2019, Millipede Inc. operates as a subsidiary of Boston Scientific Corporation.
Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.
Explorys, Inc. is a healthcare cloud-computing platform based in Cleveland, Ohio, established in 2009. The company specializes in enterprise performance management for integrated healthcare systems in the United States, offering solutions for data management, business intelligence, and population analytics. Its platform allows healthcare systems to collect and integrate diverse data types, including clinical, claims, and billing information, facilitating improved quality of care and operational efficiency. By serving providers, payers, and life sciences organizations, Explorys aims to enhance treatment outcomes and accelerate research and product development. The company's services are delivered through software-as-a-service and platform-as-a-service models, supporting critical measurement for healthcare reform and performance management. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
HNI Healthcare (formerly Hospitalists Now) is a technology-enabled physician practice management company focused on the delivery of full-service facility-based physician programs to improve the quality of patient care. The Company’s physicians, processes and technologies enable healthcare facilities to improve key quality and performance metrics through a more clinically integrated care model.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and manage their health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Protein Discovery, Inc., a life sciences company, develops and commercializes sample preparation technologies that enable protein and peptide analysis using mass spectrometry. It provides Gelfree 8100, a fractionation system that partitions complex protein mixtures into liquid-phase molecular weight fractions; Passport 1200, a sample preparation system that enriches low molecular weight proteins and peptides, and removes matrix interferences for high-throughput quantification applications; and PPS Silent Surfactant, a protein preparation reagent that solubilizes membrane proteins and cleaves to eliminate detergent interference. The company also provides UPX universal protein extraction kit for detergent extraction of proteins from cells and tissues. It serves life science researchers and drug development scientists. The company markets its products through Agilent Technologies, as well as online in the United States and internationally. Protein Discovery, Inc. was founded as Qgenics Biosciences, Inc. in 2001 and changed its name to Protein Discovery, Inc. in April 2004. The company is based in Knoxville, Tennessee.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.